EVMN Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -10.06%, SMA50 -7.2%, SMA200 -7.73%). The stock’s 14-day RSI is 44.94 (neutral), while the ATR of 2.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -27.97% below its high and over 24.67% above its low. Average 10-day trading volume of 331.59 thousand shares is significantly above the 3-month average of 213.16 thousand, indicating heightened recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $42.00 to $35.00. The high target offers 142.63% upside. The low target suggests 102.2% downside. The mean target is $39.17. This offers 126.29% upside. Evommune, Inc. earnings surprise history is a mixed track record. The quarter that ended December 11, 2025, missed forecasts by 623.77%. The prior quarter beat by -5.02%. Over the last six quarters, Apple has recorded several small beats. These include -5.02% in December 03, 2025.

Our AI price prediction model suggests that Evommune, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.1%, with price expected at $17.50 by February 20, 2026, within a range of $15.79 to $19.10 3-Month Outlook: Projected fall of -3.87%, reaching $16.64 by May 06, 2026, with a range of $16.37 to $16.88. 1-Year Outlook: Projected gain of 84.69%, with price at $31.97 by February 05, 2027, within a range of $31.69 to $32.33.

Evommune, Inc. (NYSE:EVMN) shares are flat 7.48% year-to-date currently trading near 52-week highs band. Valuation shows Evommune, Inc. trading at a premium to the broader market with a P/E of -9.23. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $39.17, suggesting 126.29% upside. Our AI forecast model points to short-term strength (1.1% over two weeks), a medium-term fall (-3.87% over three months), and a longer-term gain (84.69% over one year), with expected trading ranges indicating moderate volatility.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Evommune, Inc. (NYSE:EVMN) closed at $17.31 USD, gaining $0.65 (3.90%) from the previous close of $16.66. The stock is currently mid-range between its 52-week high and low $13.88 and $24.03. With a market capitalization of about $222.80 million, Evommune, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 227.69 thousand shares, in line with its 52-week average. Headquartered in Palo Alto, CA, Evommune, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Luis C. Pena, the company employs approximately 45 people and listed since November 06, 2025. Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Evommune, Inc. trades at a P/E ratio of -9.23, slightly below the S&P 500 average, with a price-to-sales ratio of 17.09 and a price-to-book ratio of -2.97 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.7, also above market averages.